Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity

Obesity

Volumn 23, Issue 5, 2015, Pages 965-972

  Rachakonda, Vikrant P ^a   Reeves, Valerie L ^a   Aljammal, Jules ^a   Wills, Rachel C ^a   Trybula, Joy S ^a   Delany, James P ^a   Kienesberger, Petra C ^b   Kershaw, Erin E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AUTOTAXIN; BIOLOGICAL MARKER; CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ADIPOCYTOKINE; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; PHOSPHODIESTERASE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENERGY METABOLISM; FAT CONTENT; FEMALE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER SPLEEN RATIO; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; OBESITY; PHENOTYPE; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; COMPLICATION; MIDDLE AGED; MORBID OBESITY; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADIPOKINES; ADULT; BIOMARKERS; BODY MASS INDEX; FEMALE; HUMANS; INSULIN; LEPTIN; LINEAR MODELS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; PHOSPHORIC DIESTER HYDROLASES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84928582461     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20960     Document Type: Article

References (40)

1. Farrell GC, Larter CZ,. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (Baltimore, Md) 2006; 43: S99-S112.
2. Bugianesi E, McCullough AJ, Marchesini G,. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (Baltimore, Md) 2005; 42: 987-1000.
3. Marra F, Bertolani C,. Adipokines in liver diseases. Hepatology (Baltimore, Md) 2009; 50: 957-969.
4. Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009; 29: 1431-1438.
5. Nakanaga K, Hama K, Aoki J,. Autotaxin-an LPA producing enzyme with diverse functions. J Biochem 2010; 148: 13-24.
6. Rancoule C, Dusaulcy R, Treguer K, Gres S, Attane C, Saulnier-Blache JS,. Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis. Biochimie 2014; 96: 140-143.
7. Dusaulcy R, Rancoule C, Gres S, Wanecq E, Colom A, Guigne C, et al. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J Lipid Res 2011; 52: 1247-1255.
8. Rancoule C, Attane C, Gres S, Fournel A, Dusaulcy R, Bertrand C, et al. Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice. Diabetologia 2013; 56: 1394-1402.
9. Nishimura S, Nagasaki M, Okudaira S, Aoki J, Ohmori T, Ohkawa R, et al. ENPP2 contributes to adipose tissue expansion in diet-induced obesity. Diabetes 2014; 63: 4154-4164.
10. Rancoule C, Dusaulcy R, Treguer K, Gres S, Guigne C, Quilliot D, et al. Depot-specific regulation of autotaxin with obesity in human adipose tissue. J Physiol Biochem 2012; 68: 635-644.
11. Ikeda H, Yatomi Y,. Autotaxin in liver fibrosis. Clin Chim Acta 2012; 413: 1817-1821.
12. Goodpaster BH, Delany JP, Otto AD, Kuller L, Vockley J, South-Paul JE, et al. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA 2010; 304: 1795-1802.
13. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
14. Iwasaki M, Takada Y, Hayashi M, Minamiguchi S, Haga H, Maetani Y, et al. Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation 2004; 78: 1501-1505.
15. Shores NJ, Link K, Fernandez A, Geisinger KR, Davis M, Nguyen T, et al. Non-contrasted computed tomography for the accurate measurement of liver steatosis in obese patients. Dig Dis Sci 2011; 56: 2145-2151.
16. Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239: 105-112.
17. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 2007; 41: 616-623.
18. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007; 42: 573-582.
19. Targher G,. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. J Hepatol 2006; 45: 879-881; author reply 881-872.
20. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006; 26: 39-45.
21. Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006; 44: 1167-1174.
22. Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R, et al. Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 2004; 41: 751-757.
23. Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007; 102: 1931-1938.
24. Boza C, Riquelme A, Ibanez L, Duarte I, Norero E, Viviani P, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 2005; 15: 1148-1153.
25. Wolf AM, Busch B, Kuhlmann HW, Beisiegel U,. Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters. Obes Surg 2005; 15: 228-237.
26. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005; 15: 310-315.
27. Ong JP, Pitts A, Younossi ZM,. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-612.
28. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008; 103: 2263-2271.
29. Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol 2006; 64: 679-683.
30. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J,. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (Baltimore, Md) 2004; 40: 46-54.
31. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95: 3584-3589.
32. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE,. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-1379.
33. Torres DM, Harrison SA,. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682-1698.
34. Ferry G, Tellier E, Try A, Gres S, Naime I, Simon MF, et al. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 2003; 278: 18162-18169.
35. Gesta S, Simon MF, Rey A, Sibrac D, Girard A, Lafontan M, et al. Secretion of a lysophospholipase D activity by adipocytes: involvement in lysophosphatidic acid synthesis. J Lipid Res 2002; 43: 904-910.
36. Boucher J, Quilliot D, Praderes JP, Simon MF, Gres S, Guigne C, et al. Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 2005; 48: 569-577.
37. Jansen S, Andries M, Vekemans K, Vanbilloen H, Verbruggen A, Bollen M,. Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett 2009; 284: 216-221.
38. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Tomiya T, et al. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci 2007; 81: 1009-1015.
39. Simon MF, Daviaud D, Pradere JP, Gres S, Guigne C, Wabitsch M, et al. Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2. J Biol Chem 2005; 280: 14656-14662.
40. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (Baltimore, Md) 2002; 36: 403-409.